Acepodia, Inc. (TPEX:6976)
Taiwan · Delayed Price · Currency is TWD 12.70
-0.45 (-3.42%)
Mar 4, 2026, 12:10 PM CST
Acepodia Revenue
Acepodia had revenue of 185.00K TWD in the half year ending June 30, 2025. This brings the company's revenue in the last twelve months to 301.00K, down -98.22% year-over-year. In the year 2024, Acepodia had annual revenue of 427.00K, down -97.43%.
Revenue (ttm)
301.00K
Revenue Growth
-98.22%
P/S Ratio
25,435.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 427.00K | -16.17M | -97.43% |
| Dec 31, 2023 | 16.59M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.35B |
| PharmaEngine | 2.51B |
| Adimmune | 1.20B |
| Savior Lifetec | 1.16B |
| Mycenax Biotech | 649.64M |
| OBI Pharma | 49.29M |
| TaiGen Biopharmaceuticals Holdings | 38.75M |
| Gongwin Biopharm Holdings | 37.46M |